These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 11490238)
1. Safety and efficacy of exisulind for treatment of recurrent prostate cancer after radical prostatectomy. Goluboff ET; Prager D; Rukstalis D; Giantonio B; Madorsky M; Barken I; Weinstein IB; Partin AW; Olsson CA; J Urol; 2001 Sep; 166(3):882-6. PubMed ID: 11490238 [TBL] [Abstract][Full Text] [Related]
2. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031 [TBL] [Abstract][Full Text] [Related]
4. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288 [TBL] [Abstract][Full Text] [Related]
5. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382 [TBL] [Abstract][Full Text] [Related]
7. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709 [TBL] [Abstract][Full Text] [Related]
8. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. Ward JF; Blute ML; Slezak J; Bergstralh EJ; Zincke H J Urol; 2003 Nov; 170(5):1872-6. PubMed ID: 14532796 [TBL] [Abstract][Full Text] [Related]
9. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score. Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy. Bajaj GK; Zhang Z; Garrett-Mayer E; Drew R; Sinibaldi V; Pili R; Denmeade SR; Carducci MA; Eisenberger MA; DeWeese TL Urology; 2007 Mar; 69(3):526-31. PubMed ID: 17382158 [TBL] [Abstract][Full Text] [Related]
11. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Smith MR; Manola J; Kaufman DS; George D; Oh WK; Mueller E; Slovin S; Spiegelman B; Small E; Kantoff PW Cancer; 2004 Oct; 101(7):1569-74. PubMed ID: 15468186 [TBL] [Abstract][Full Text] [Related]
12. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328 [TBL] [Abstract][Full Text] [Related]
13. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC; J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735 [TBL] [Abstract][Full Text] [Related]
14. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249 [TBL] [Abstract][Full Text] [Related]
15. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. Freedland SJ; Kane CJ; Presti JC; Terris MK; Amling CL; Dorey F; Aronson WJ J Urol; 2003 Mar; 169(3):969-73. PubMed ID: 12576824 [TBL] [Abstract][Full Text] [Related]